Yang Shang-You, Mayton Lois, Wu Bin, Goater J Jeffrey, Schwarz Edward M, Wooley Paul H
Wayne State University School of Medicine, Detroit, Michigan 48201, USA.
Arthritis Rheum. 2002 Sep;46(9):2514-23. doi: 10.1002/art.10527.
Osteoprotegerin (OPG), a natural negative regulator of osteoclastogenesis and bone resorption, may be a potential therapeutic agent for treatment of osteolysis-associated prosthetic joint loosening. Using an in vivo adeno-associated virus (AAV)-mediated gene transfer technique, this study was designed to evaluate the protective effects of OPG transgene against orthopedic wear debris-induced bone loss in a murine model of osteolysis.
Bone tissue was implanted into established pouches on BALB/c mice, followed by the introduction of ultra-high-molecular-weight polyethylene (UHMWPE) particles to provoke inflammation and osteolysis. The viruses encoding human OPG gene (rAAV-hOPG) or beta-galactosidase marker gene (rAAV-LacZ) were injected into the air pouches, and the tissue was harvested 7 days after viral infection for histologic and molecular analyses.
Successful transgene expression was confirmed by the detection of OPG by enzyme-linked immunosorbent assay and positive X-Gal staining of pouch tissue (LacZ). Real-time polymerase chain reaction indicated significant diminishment of messenger RNA expression of osteoclast markers in OPG-transduced pouches compared with rAAV-LacZ-transduced pouches. The transduction and expression of OPG also markedly decreased the gene copies of the biologic receptor activator of nuclear factor kappaB. The expression of OPG in the bone-implanted pouch reduced bone calcium release by a mean of 39% compared with the calcium release in the other 2 groups. Computerized image analysis revealed that expression of OPG significantly protected against bone collagen loss.
OPG gene transfer mediated by rAAV effectively protects against particulate polyethylene-induced bone resorption in this experimental model. Data suggest that gene transfer using rAAV-OPG may be a feasible and effective therapeutic candidate to treat or prevent wear debris-associated osteolysis and aseptic loosening.
骨保护素(OPG)是破骨细胞生成和骨吸收的天然负性调节因子,可能是治疗与骨溶解相关的人工关节松动的潜在治疗药物。本研究采用体内腺相关病毒(AAV)介导的基因转移技术,旨在评估OPG转基因对小鼠骨溶解模型中骨科磨损颗粒诱导的骨质流失的保护作用。
将骨组织植入BALB/c小鼠已建立的皮下囊中,随后引入超高分子量聚乙烯(UHMWPE)颗粒以引发炎症和骨溶解。将编码人OPG基因的病毒(rAAV-hOPG)或β-半乳糖苷酶标记基因(rAAV-LacZ)注入皮下囊,病毒感染7天后收获组织进行组织学和分子分析。
通过酶联免疫吸附测定法检测OPG以及对皮下囊组织进行阳性X-Gal染色(LacZ)证实了转基因的成功表达。实时聚合酶链反应表明,与rAAV-LacZ转导的皮下囊相比,OPG转导的皮下囊中破骨细胞标志物的信使RNA表达显著降低。OPG的转导和表达也显著降低了核因子κB生物受体激活剂的基因拷贝数。与其他两组的钙释放相比,骨植入皮下囊中OPG的表达使骨钙释放平均减少了39%。计算机图像分析显示,OPG的表达显著保护了骨胶原的流失。
在本实验模型中,rAAV介导的OPG基因转移有效地保护了颗粒状聚乙烯诱导的骨吸收。数据表明,使用rAAV-OPG进行基因转移可能是治疗或预防磨损颗粒相关骨溶解和无菌性松动的一种可行且有效的治疗候选方法。